Search Results - Uzzo, Robert, Prof

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

    Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial by Haas, Naomi B, Dr, Manola, Judith, MS, Uzzo, Robert G, Prof, Flaherty, Keith T, MD, Wood, Christopher G, Prof, Kane, Christopher, Prof, Jewett, Michael, Prof, Dutcher, Janice P, Prof, Atkins, Michael B, Prof, Pins, Michael, Prof, Wilding, George, Prof, Cella, David, Prof, Wagner, Lynne, Prof, Matin, Surena, Prof, Kuzel, Timothy M, Prof, Sexton, Wade J, Prof, Wong, Yu-Ning, MD, Choueiri, Toni K, MD, Pili, Roberto, Prof, Puzanov, Igor, MD, Kohli, Manish, MD, Stadler, Walter, Prof, Carducci, Michael, Prof, Coomes, Robert, DiPaola, Robert S, Prof

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial

    Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with... by Mitin, Timur, Dr, Hunt, Daniel, PhD, Shipley, William U, Prof, Kaufman, Donald S, Prof, Uzzo, Robert, Prof, Wu, Chin-Lee, MD, Buyyounouski, Mark K, MD, Sandler, Howard, Prof, Zietman, Anthony L, Prof

    Published in The lancet oncology
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: